Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02484443




Registration number
NCT02484443
Ethics application status
Date submitted
26/06/2015
Date registered
29/06/2015
Date last updated
26/10/2023

Titles & IDs
Public title
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Scientific title
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Secondary ID [1] 0 0
NCI-2015-01001
Secondary ID [2] 0 0
NCI-2015-01001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Malignant Neoplasm in the Lung 0 0
Metastatic Osteosarcoma 0 0
Recurrent Osteosarcoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bone
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Children's - Other
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Dinutuximab
Other interventions - Laboratory Biomarker Analysis
Other interventions - Pharmacological Study
Other interventions - Sargramostim

Experimental: Treatment (sargramostim and dinutuximab) - Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.


Other interventions: Dinutuximab
Given IV

Other interventions: Laboratory Biomarker Analysis
Correlative studies

Other interventions: Pharmacological Study
Correlative studies

Other interventions: Sargramostim
Given SC
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease Control
Timepoint [1] 0 0
12 months after study enrollment
Secondary outcome [1] 0 0
T 1/2 Alpha of the Serum Concentration of Dinutuximab
Timepoint [1] 0 0
Cycle 1 Day 4 and Day 7: pre-infusion, hour 4-6, end of infusion, 4-8 hours post infusion. Once between days 11-17. Cycle 2 Day 0 or 1
Secondary outcome [2] 0 0
T 1/2 Beta of the Serum Concentration of Dinutuximab
Timepoint [2] 0 0
Cycle 1 Day 4 and Day 7: pre-infusion, hour 4-6, end of infusion, 4-8 hours post infusion. Once between days 11-17. Cycle 2 Day 0 or 1
Secondary outcome [3] 0 0
Maximum of Concentration (Cmax) of the Serum Concentration Dinutuximab
Timepoint [3] 0 0
Cycle 1 Day 4 and Day 7: pre-infusion, hour 4-6, end of infusion, 4-8 hours post infusion. Once between days 11-17. Cycle 2 Day 0 or 1
Secondary outcome [4] 0 0
Area Under the Curve (AUC)0 to Infinity of Serum Dinutuximab
Timepoint [4] 0 0
Cycle 1 Day 4 and Day 7: pre-infusion, hour 4-6, end of infusion, 4-8 hours post infusion. Once between days 11-17. Cycle 2 Day 0 or 1
Secondary outcome [5] 0 0
Number of Cycles Where an Unacceptable Toxicity as Defined in the Protocol Using The National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 Was Observed
Timepoint [5] 0 0
5 cycles of protocol therapy planned as 140 days

Eligibility
Key inclusion criteria
- Patients must have histologic diagnosis of osteosarcoma at original diagnosis

- Patients must have had at least one episode of disease recurrence in the lungs without
limitation on number of episodes of recurrence as long as they meet the following
criteria:

- Surgical resection of all possible sites of suspected pulmonary metastases in
order to achieve a complete remission within 4 weeks prior to study enrollment**

- Pathologic confirmation of metastases from at least one of the resected sites

- For patients with bilateral pulmonary metastases, resection must be
performed from both lungs and the study enrollment must be within 4 weeks
from date of the last lung surgery

- Note: If surgery related changes such as atelectasis are seen on the
post-operative computed tomography (CT) scan, patients will remain eligible to
enroll as long as the operating surgeon believes that all sites of metastases
were resected; patients with positive microscopic margins will be eligible to
enroll

- Patient must have adequate tumor specimen available for submission

- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- Myelosuppressive anti-cancer therapy: must not have been received within 2 weeks
of study entry (4 weeks if prior nitrosourea)

- Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy
with a biologic agent

- Radiation therapy (RT): >= 2 weeks for local palliative radiation therapy (RT)
(small port); >= 6 weeks must have elapsed if prior craniospinal RT or if >= 50%
radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone
marrow (BM) radiation

- Surgery: >= 2 weeks from last major surgery, including pulmonary metastasectomy,
with the exclusion of a central line placement and core needle or small open
biopsies

- Patient must not have received pegfilgrastim within 14 days of enrollment

- Patient must not have received filgrastim (G-CSF, Neupogen) within 7 days of
enrollment

- Patient must not have received immune suppressants: corticosteroids (for other than
allergic reactions and anaphylaxis), cyclosporine or tacrolimus within 7 days of
enrollment

- Note: the use of topical and/or inhalational steroids is allowed

- Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells
[WBC]) is at least 1000/uL

- Platelet count >= 50,000/uL

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or

- A serum creatinine based on age/gender as follows:

- 1 month to < 6 months: 0.4 (male) 0.4 (female)

- 6 months to < 1 year: 0.5 (male), 0.5 (female)

- 1 to < 2 years: 0.6 (male), 0.6 (female)

- 2 to < 6 years: 0.8 (male), 0.8 (female)

- 6 to < 10 years: 1 (male), 1 (female)

- 10 to < 13 years: 1.2 (male), 1.2 (female)

- 13 to < 16 years: 1.5 (male), 1.4 (female)

- >= 16 years: 1.7 (male), 1.4 (female)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110
U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)

- Serum albumin >= 2 g/dL

- Baseline electrocardiogram (EKG) shows normal corrected QT interval (QTc) interval of
=< 470 milliseconds (ms)

- Shortening fraction of >= 27% by echocardiogram, or

- Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram

- No evidence of dyspnea at rest, no history of exercise intolerance, and a pulse
oximetry > 94%

- Patient has no known history of seizure disorder

- Central nervous system (CNS) toxicity including peripheral neuropathy =< grade 2
Minimum age
No limit
Maximum age
29 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with distant bone metastases at original diagnosis or relapse (patients with
only skip lesions will be eligible)

- Patients with concurrent local and pulmonary recurrence at the time of enrollment;
note: patients who had local recurrence previously that has been treated and now
present with an isolated pulmonary recurrence and meet the surgical resection criteria
stated above will be eligible

- Patients with primary refractory disease with progression of the primary tumor on
initial therapy

- Patients with CNS disease or other sites of extra-pulmonary metastases at the time of
most recent episode of disease recurrence preceding enrollment

- Patients with a prior hypersensitivity reaction to sargramostim

- Patients who have received prior anti-GD2 therapy, including chimeric antigen receptor
(CAR) T cells directed against GD2 antigen

- Female patients who are pregnant are ineligible

- Lactating females are not eligible unless they have agreed not to breastfeed their
infants

- Female patients of childbearing potential are not eligible unless a negative pregnancy
test result has been obtained

- Sexually active patients of reproductive potential are not eligible unless they have
agreed to use an effective contraceptive method for the duration of their study
participation; patients should maintain adequate contraception for a minimum of 2
months after the last dose of ch14.18 (dinutuximab)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/02/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/09/2023
Sample size
Target
Accrual to date
Final
41
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [3] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [4] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 0 0
Women's and Children's Hospital-Adelaide - North Adelaide
Recruitment hospital [6] 0 0
Monash Medical Center-Clayton Campus - Clayton
Recruitment hospital [7] 0 0
Royal Children's Hospital - Parkville
Recruitment hospital [8] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment postcode(s) [1] 0 0
2310 - Hunter Regional Mail Centre
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
5006 - North Adelaide
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
3052 - Parkville
Recruitment postcode(s) [8] 0 0
6008 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
District of Columbia
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Hawaii
Country [12] 0 0
United States of America
State/province [12] 0 0
Idaho
Country [13] 0 0
United States of America
State/province [13] 0 0
Illinois
Country [14] 0 0
United States of America
State/province [14] 0 0
Indiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Iowa
Country [16] 0 0
United States of America
State/province [16] 0 0
Kentucky
Country [17] 0 0
United States of America
State/province [17] 0 0
Louisiana
Country [18] 0 0
United States of America
State/province [18] 0 0
Maine
Country [19] 0 0
United States of America
State/province [19] 0 0
Maryland
Country [20] 0 0
United States of America
State/province [20] 0 0
Massachusetts
Country [21] 0 0
United States of America
State/province [21] 0 0
Michigan
Country [22] 0 0
United States of America
State/province [22] 0 0
Minnesota
Country [23] 0 0
United States of America
State/province [23] 0 0
Mississippi
Country [24] 0 0
United States of America
State/province [24] 0 0
Missouri
Country [25] 0 0
United States of America
State/province [25] 0 0
Nebraska
Country [26] 0 0
United States of America
State/province [26] 0 0
Nevada
Country [27] 0 0
United States of America
State/province [27] 0 0
New Hampshire
Country [28] 0 0
United States of America
State/province [28] 0 0
New Jersey
Country [29] 0 0
United States of America
State/province [29] 0 0
New York
Country [30] 0 0
United States of America
State/province [30] 0 0
North Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
North Dakota
Country [32] 0 0
United States of America
State/province [32] 0 0
Ohio
Country [33] 0 0
United States of America
State/province [33] 0 0
Oklahoma
Country [34] 0 0
United States of America
State/province [34] 0 0
Oregon
Country [35] 0 0
United States of America
State/province [35] 0 0
Pennsylvania
Country [36] 0 0
United States of America
State/province [36] 0 0
South Carolina
Country [37] 0 0
United States of America
State/province [37] 0 0
South Dakota
Country [38] 0 0
United States of America
State/province [38] 0 0
Tennessee
Country [39] 0 0
United States of America
State/province [39] 0 0
Texas
Country [40] 0 0
United States of America
State/province [40] 0 0
Utah
Country [41] 0 0
United States of America
State/province [41] 0 0
Vermont
Country [42] 0 0
United States of America
State/province [42] 0 0
Virginia
Country [43] 0 0
United States of America
State/province [43] 0 0
Washington
Country [44] 0 0
United States of America
State/province [44] 0 0
West Virginia
Country [45] 0 0
United States of America
State/province [45] 0 0
Wisconsin
Country [46] 0 0
Canada
State/province [46] 0 0
Alberta
Country [47] 0 0
Canada
State/province [47] 0 0
Manitoba
Country [48] 0 0
Canada
State/province [48] 0 0
Nova Scotia
Country [49] 0 0
Canada
State/province [49] 0 0
Ontario
Country [50] 0 0
Canada
State/province [50] 0 0
Quebec
Country [51] 0 0
New Zealand
State/province [51] 0 0
Auckland
Country [52] 0 0
New Zealand
State/province [52] 0 0
Christchurch
Country [53] 0 0
Puerto Rico
State/province [53] 0 0
San Juan

Funding & Sponsors
Primary sponsor type
Government body
Name
National Cancer Institute (NCI)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This phase II trial studies how well dinutuximab works when given with sargramostim in
treating patients with osteosarcoma that has come back after treatment (recurrent).
Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them.
Sargramostim may help the body increase the amount of white blood cells it produces, which
help the body fight off infections. Giving dinutuximab with sargramostim may work better and
kill more cancer cells.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02484443
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pooja Hingorani
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02484443